https://www.yiliao.com/index.php?action=history&feed=atom&title=TSC1
TSC1 - 版本历史
2026-04-19T02:55:27Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=TSC1&diff=311687&oldid=prev
2025年12月29日 (一) 17:13 77921020
2025-12-29T17:13:58Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 17:13的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">360px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">380px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=TSC1&diff=311686&oldid=prev
2025年12月29日 (一) 17:13 77921020
2025-12-29T17:13:43Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 17:13的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">340px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">360px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=TSC1&diff=311685&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T17:13:11Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>TSC1</strong>（Tuberous Sclerosis Complex 1），编码蛋白 <strong>Hamartin</strong>（错构素）。它是细胞生长控制中枢——<strong>mTORC1 信号通路</strong>的关键负调控因子。在细胞质中，TSC1 必须与 <strong>TSC2</strong>（Tuberin）形成紧密的异源二聚体复合物，作为 GAP（GTPase Activating Protein）抑制小 G 蛋白 Rheb 的活性，从而阻断 mTORC1 的过度激活。作为经典的<strong>肿瘤抑制基因</strong>，TSC1 的生殖系突变导致常染色体显性遗传病——<strong>[[结节性硬化症]] (TSC)</strong>，表现为全身多器官的错构瘤（如脑、肾、心、肺）。此外，TSC1 的体细胞突变也常见于<strong>[[膀胱癌]]</strong>和部分肾细胞癌中。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 340px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">TSC1 (Hamartin) · 基因档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gene & Protein Profile (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
[[文件:TSC1_TSC2_mTOR_Pathway.png|100px|TSC1-TSC2 复合物抑制 mTOR]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">mTOR 通路“刹车片”</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>TSC1</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">编码蛋白</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">Hamartin (错构素)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">9q34.13</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">7248</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">HGNC ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">12362</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">UniProt</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">Q92574</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">~130 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">关键伙伴</th><br />
<td style="padding: 8px 12px; color: #0f172a;">TSC2 (Tuberin)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：Hamartin 与 Tuberin 的协奏</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
TSC1 本身不具备催化活性，它的核心功能是作为 TSC2 的<strong>分子伴侣 (Chaperone)</strong>，防止 TSC2 被泛素化降解并将其定位到溶酶体膜表面。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>TSC 复合物形成：</strong> TSC1 (Hamartin) 通过其螺旋卷曲结构域与 TSC2 (Tuberin) 结合。TSC2 含有 GAP（GTPase Activating Protein）结构域，是真正的功能执行者。没有 TSC1，TSC2 极不稳定；因此，TSC1 的缺失在功能上等同于 TSC2 的缺失。</li><br />
<li style="margin-bottom: 12px;"><strong>抑制 Rheb-mTOR 轴：</strong> TSC1-TSC2 复合物作用于小 G 蛋白 <strong>Rheb</strong>，促进 Rheb 将结合的 GTP 水解为 GDP。Rheb-GDP 无法激活 <strong>mTORC1</strong>。因此，TSC 复合物就像 mTOR 的“刹车”。</li><br />
<li style="margin-bottom: 12px;"><strong>上游调控枢纽：</strong> 该复合物整合多种信号。<br />
<br> - <strong>生长因子 (Insulin/IGF-1)：</strong> 通过 AKT 磷酸化 TSC2，导致复合物解离或失活，从而释放 mTORC1（促进生长）。<br />
<br> - <strong>能量匮乏 (AMPK)：</strong> 磷酸化并激活 TSC2，增强对 mTORC1 的抑制（保存能量）。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床景观：全身性错构瘤病</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
TSC1 的临床意义主要集中在遗传性综合征和特定的泌尿系统肿瘤。<br />
</p><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">变异性质</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床特征</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">结节性硬化症 (TSC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">生殖系杂合突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">常染色体显性遗传。特征为多器官错构瘤：脑部（皮层结节、<strong>SEGA</strong>）、肾脏（<strong>血管平滑肌脂肪瘤 AML</strong>）、心脏（横纹肌瘤）和皮肤（面部血管纤维瘤）。TSC1 突变患者症状通常比 TSC2 突变患者稍轻。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">淋巴管肌瘤病 (LAM)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞/生殖系 (TSC2更常见)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">主要发生于育龄期女性的肺部囊性疾病。无论是散发性 LAM 还是 TSC 相关 LAM，其本质都是 TSC1/2 缺失导致的 mTORC1 过度激活。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">膀胱尿路上皮癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞突变 (~10-15%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在膀胱癌中，TSC1 是常见的突变基因之一。突变通常导致 mTOR 通路激活，此类患者可能对 mTOR 抑制剂（如 Everolimus）治疗敏感。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">肾嗜酸细胞瘤 / RCC</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">TSC1/2 突变的肾癌往往具有独特的形态学特征（如嗜酸性胞浆），被归类为 TSC 突变型肾细胞癌。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：mTOR 抑制剂的胜利</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
基于对 TSC1 分子机制的理解，mTOR 抑制剂（Rapalogs）已成为治疗 TSC 相关肿瘤的标准疗法。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>mTORC1 抑制剂：</strong><br />
<br><strong>[[Everolimus]]</strong> (依维莫司) 和 <strong>[[Sirolimus]]</strong> (西罗莫司/雷帕霉素)。<br />
<br><span style="font-size: 0.9em; color: #64748b;">*适应症：获批用于治疗 TSC 相关的<strong>室管膜下巨细胞星形细胞瘤 (SEGA)</strong>、<strong>肾血管平滑肌脂肪瘤 (AML)</strong> 以及与 TSC 无关的晚期肾癌和乳腺癌。<br />
<br>*疗效：能显著缩小肿瘤体积，改善癫痫控制（作为辅助治疗）。</span><br />
</li><br />
<li style="margin-bottom: 12px;"><strong>局部治疗：</strong><br />
<br>外用西罗莫司乳膏可有效治疗 TSC 患者的面部血管纤维瘤，减轻红斑和皮损，且副作用极小。</li><br />
<li style="margin-bottom: 12px;"><strong>膀胱癌探索：</strong><br />
<br>虽然 TSC1 突变在膀胱癌中常见，但 mTOR 抑制剂单药治疗效果有限（主要因反馈激活 AKT），目前正在探索联合疗法（如联合 PI3K 抑制剂或免疫治疗）。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>mTORC1：</strong> TSC1 下游的直接效应复合物，控制蛋白质合成和细胞生长。</li><br />
<li style="margin-bottom: 12px;"><strong>SEGA：</strong> 脑室内的良性肿瘤，若不治疗可导致脑积水，是 TSC1 突变的标志性病变。</li><br />
<li style="margin-bottom: 12px;"><strong>AML (Angiomyolipoma)：</strong> 肾脏血管平滑肌脂肪瘤，破裂出血是 TSC 患者的主要死因之一。</li><br />
<li style="margin-bottom: 12px;"><strong>Rheb：</strong> 被 TSC1-TSC2 抑制的小 G 蛋白。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>van Slegtenhorst M, et al. (1997).</strong> <em>Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.</em> <strong>Science</strong>. <br><br />
<span style="color: #475569;">[学术点评]：发现性文献。通过位置克隆法成功鉴定了 TSC1 基因，证实其编码一种全新的亲水蛋白 Hamartin，解开了结节性硬化症一半的遗传谜题。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Inoki K, et al. (2002).</strong> <em>TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.</em> <strong>Nature Cell Biology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：机制里程碑。首次建立了 PI3K/AKT 通路与 TSC1/2 复合物以及 mTOR 之间的直接联系，阐明了胰岛素促进细胞生长的分子路径。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Franz DN, et al. (2013).</strong> <em>Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.</em> <strong>The Lancet</strong>. <br><br />
<span style="color: #475569;">[学术点评]：改变临床实践的试验。EXIST-1 试验证明 Everolimus 能有效缩小 SEGA 体积，使其成为首个获批治疗 TSC 中枢神经系统病变的药物。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Bissler JJ, et al. (2013).</strong> <em>Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.</em> <strong>The Lancet</strong>. <br><br />
<span style="color: #475569;">[学术点评]：EXIST-2 试验。确立了 mTOR 抑制剂在治疗 TSC 相关肾脏 AML 中的地位，显著降低了肿瘤体积和出血风险。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[5] <strong>Iyer G, et al. (2013).</strong> <em>Genome sequencing identifies a basis for everolimus sensitivity.</em> <strong>Science</strong>. <br><br />
<span style="color: #475569;">[学术点评]：精准医疗案例。通过全基因组测序发现，一名对 Everolimus 产生“非凡反应”的膀胱癌患者携带 TSC1 突变，从而揭示了 TSC1 作为 mTOR 抑制剂疗效预测因子的潜力。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">TSC1 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center; text-decoration: none;"><br />
[[结节性硬化症]] • [[mTOR抑制剂]] • [[Everolimus]] • [[TSC2]] • [[Rheb]] • [[错构瘤]] • [[LAM]] • [[肾血管平滑肌脂肪瘤]]<br />
</div><br />
</div><br />
<br />
</div></div>
77921020